Tempero M A, Kessinger A
J Surg Oncol. 1982 Nov;21(3):159-61. doi: 10.1002/jso.2930210305.
Ten patients with advanced ovarian carcinoma were treated with hexamethylmelamine and melphalan after failing first-line combination chemotherapy. In eight patients residual disease was evident only at second-look laparotomy. Surgical debulking was accomplished in four patients but only two patients had residual disease of less than 2 cm. Two of these four patients are alive without evidence of disease to 20 and 24 months. The remaining patients have expired (median survival 6 months). The combination of hexamethylmelamine and melphalan after surgical debulking at second-look operation may improve the salvage of patients with advanced ovarian carcinoma.
10例晚期卵巢癌患者在一线联合化疗失败后接受六甲蜜胺和马法兰治疗。8例患者仅在二次剖腹探查时发现残留病灶。4例患者完成了肿瘤细胞减灭术，但只有2例患者残留病灶小于2 cm。这4例患者中有2例存活，无疾病证据，分别为20个月和24个月。其余患者均已死亡（中位生存期6个月）。在二次剖腹探查手术进行肿瘤细胞减灭术后使用六甲蜜胺和马法兰联合治疗，可能会提高晚期卵巢癌患者的挽救率。
